CLDI insider transaction filings
Calidi Biotherapeutics, Inc. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen CLDI transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Schoeneck James A — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Jackson Andrew C. — Chief Financial Officer | Grant/award (A): 14,000 (derivative) | EDGAR |
| 2026-08-19 | 4 | Stewart Alan R. — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Leftwich Scott — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Peoples George — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Fernandez Santidrian Antonio — Chief Scientific Officer | Grant/award (A): 16,000 (derivative) | EDGAR |
| 2026-08-19 | 4 | Poma Eric E — Chief Executive Officer | Grant/award (A): 32,000 (derivative) | EDGAR |
| 2025-12-16 | 4 | Camaisa Allan — Director | Sale (S): 850 @ $1.46 | EDGAR |
| 2025-09-05 | 4 | Fernandez Santidrian Antonio — Chief Scientific Officer | Grant/award (A): 35,000 (derivative) | EDGAR |
| 2025-09-05 | 4 | Jackson Andrew C. — Chief Financial Officer | Grant/award (A): 30,000 (derivative) | EDGAR |
| 2025-09-05 | 4 | Poma Eric E — Chief Executive Officer | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Leftwich Scott — Director | Purchase (P): 125,000 @ $2 · Purchase (P): 125,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Jackson Andrew C. — Chief Financial Officer | Purchase (P): 2,500 @ $2 · Purchase (P): 2,500 (derivative) | EDGAR |
| 2025-08-25 | 4 | Schoeneck James A — Director | Purchase (P): 75,000 @ $2 · Purchase (P): 75,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Poma Eric E — Chief Executive Officer, Director | Purchase (P): 25,000 @ $2 · Purchase (P): 25,000 (derivative) | EDGAR |
| 2025-07-15 | 4 | Peoples George — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Leftwich Scott — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Stewart Alan R. — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Schoeneck James A — Director | Grant/award (A): 164,493 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | Poma Eric E — Chief Executive Officer, Director | Grant/award (A): 726,412 (derivative) | EDGAR |
Recent 8-K events — Calidi Biotherapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CLDI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →